Drug Profile
423557
Alternative Names: NPSP790; SB-423557Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator NPS Pharmaceuticals
- Developer Takeda
- Class Osteoporosis therapies; Small molecules
- Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypocalcaemia
- Discontinued Osteoporosis
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hypocalcaemia(In volunteers) in USA (PO)
- 21 Feb 2015 NPS Pharmaceuticals has been acquired by Shire